KURA - Kura Oncology, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 13.70 |
| Open | 13.70 |
| Bid | 13.05 x 1100 |
| Ask | 13.14 x 1200 |
| Day's Range | 13.03 - 13.70 |
| 52 Week Range | 9.49 - 19.93 |
| Volume | |
| Avg. Volume | 631,026 |
| Market Cap | 924.606M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.04 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.64 |
Fair Value
Related Research
TipRanksOver 100% Upside: Analysts See an Appealing Entry Point in These 2 Small-Cap Stocks
If there’s one way to describe the markets recently, that would be top-heavy. The mega-caps, the largest US companies, have been outperforming the broader indexes, and by their very size they are pulling the rest of the markets along. To give an idea of the scale, the three largest S&P-listed companies are Apple, Microsoft, and Alphabet; together, they have a combined market cap over $6.9 trillion and make up a big chunk of the S&P 500’s total value. That $6.9 trillion is a higher market cap tha
GlobeNewswireKura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress
– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 – – Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral session on Sunday, June 11, 2023 – – Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12, 2023 – SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for
- GlobeNewswire
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences: A fireside chat at the virtual TD Cowen 4th Annual Oncology Innovation Summit at 1:30 p.m. ET / 10:30 a.m. PT on May 3
Insider MonkeyKura Oncology, Inc. (NASDAQ:KURA) Q1 2023 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2023 Earnings Call Transcript May 10, 2023 Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.54. Operator: Good afternoon, ladies and gentlemen, and welcome to the Q1 2023 Kura Oncology, Inc. Earnings Conference Call. [Operator Instructions]. This call is being recorded on Wednesday, May 10, 2023. […]
- Thomson Reuters StreetEvents
Q1 2023 Kura Oncology Inc Earnings Call
Q1 2023 Kura Oncology Inc Earnings Call
- GlobeNewswire
Kura Oncology Reports First Quarter 2023 Financial Results
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients in the second quarter of 2023 – – Preclinical data highlighting potential use of FTIs in combination with multiple targeted therapies presented at AACR – – IND for KO-2806
- GlobeNewswire
Kura Oncology to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 11:00 a.m. ET / 8:00 a.m. PT on May 16, 2023. A live audio webcast of the firesid
- GlobeNewswire
Kura Oncology to Report First Quarter 2023 Financial Results
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a co
InvestorPlace3 Under-the-Radar Stocks That AI Predicts Will Soar in May
Investors looking for help finding the best under-the-radar stocks may have a new ally: the AI chatbot. Using the prompt “publicly traded companies that may be on the cusp of breaking out in popularity in May 2023,” the chatbot created a list of five top stocks to dig into. I was flattered to find that the AI list included several hidden gem stocks I put on a list of undiscovered stocks in Feb. Even better, the chatbot offered up some thoughts as to why these stocks might be good buys for May. I
- GlobeNewswire
Kura Oncology to Participate in Stifel Targeted Oncology Days
SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m. ET / 10:00 a.m. PT on April 25, 2023. A live audio webcast of the fireside chat wi
- GlobeNewswire
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence of adaptive resistance – – Company preparing to initiate Phase 1 dose-escalation trial (FIT-001) of KO-2806, a next-generation FTI – SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical
- GlobeNewswire
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to
- GlobeNewswire
Kura Oncology to Participate in Upcoming Investor Conferences
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences: A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. P
Insider MonkeyKura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Greetings, and welcome to Kura Oncology’s Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like […]
- Thomson Reuters StreetEvents
Q4 2022 Kura Oncology Inc Earnings Call
Q4 2022 Kura Oncology Inc Earnings Call
- GlobeNewswire
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA – – $25 million strategic equity investment from Bristol Myers Sq
- GlobeNewswire
Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and
InvestorPlace7 Undiscovered Stocks to Watch for the Next Big Thing
Stocks are showing signs of life in 2023. And if you have a tolerance for risk and are willing to look for stocks to trade, the small-cap sector is one area to find stocks to watch. Historically, small-cap stocks tend to perform very well when market sentiment is moving from bearish to bullish. These stocks can be volatile, but at the same time, small increases in their stock price can mean big gains for your portfolio. To find these stocks to watch, I used a stock screener looking for small-cap
- GlobeNewswire
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe – SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in its KOMET-001 Phase 2 registr
- GlobeNewswire
Kura Oncology to Participate in SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 5:00 p.m. ET / 2:00 p.m. PT on February 14, 2023. A live audio webcast of the fir
TipRanks2 “Strong Buy” Small Cap Stocks That Can Rip Higher in 2023
Considering his status, only a brave financial prognosticator would tell investors to ignore some advice from Warren Buffet. That, however, is what Bank of America's Savita Subramanian currently recommends investors should do. While the investing sage has often said that the best strategy for retail investors is to purchase and hold an index fund that keeps track of the S&P 500, Subramanian, who is the head of US equity and quantitative strategy at BofA, does not think that is the best way forwa
- GlobeNewswire
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors. The Company intends to evaluate safet
Simply Wall St.An Intrinsic Calculation For Kura Oncology, Inc. (NASDAQ:KURA) Suggests It's 48% Undervalued
Today we will run through one way of estimating the intrinsic value of Kura Oncology, Inc. ( NASDAQ:KURA ) by...
BenzingaKura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting
Kura Oncology Inc (NASDAQ: KURA) announced updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML). Ziftomenib demonstrated optimal clinical benefit at 600 mg with a 30% CR rate (6/20) in patients with NPM1-mutant AML, compared to 17% (1/6) at 200 mg. Notably, four NPM1-mutant patients who achieved a CR at 600 mg had IDH and/or FLT3 co-mutations. Related: Kura Oncology Reports Preliminary Proof Of Mechanism Data Fro
- GlobeNewswire
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg –– 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive Type C meeting with FDA –– Company expects to dose first patient in Phase 2 registration-directed trial in NPM1-mutant AML in first quarter of 2023 –– Further clinical development of KTM2A-